RA
TEVA icon

Rise Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Rise Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-250
Closed -$4.51K – 1217
2024
Q3 		$4.51K Sell
250
-240
-49% -$4.2K ﹤0.01% 1090
2024
Q2 		$7.97K Hold
490
– – ﹤0.01% 1047
2024
Q1 		$6.92K Hold
490
– – ﹤0.01% 1076
2023
Q4 		$5.12K Hold
490
– – ﹤0.01% 377
2023
Q3 		$5K Hold
490
– – ﹤0.01% 378
2023
Q2 		$3.69K Sell
490
-300
-38% -$2.43K ﹤0.01% 444
2023
Q1 		$6.99K Hold
790
– – 0.01% 411
2022
Q4 		$7.21K Hold
790
– – 0.01% 397
2022
Q3 		$6K Hold
790
– – 0.01% 424
2022
Q2 		$6K Hold
790
– – 0.01% 423
2022
Q1 		$7K Hold
790
– – 0.01% 378
2021
Q4 		$6.33K Buy
+790
New +$7.13K 0.01% 377

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Rise Advisors's TEVA Position: Q4 2024 in Review

Rise Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 250 shares — an estimated $4.51K sold.

Rise Advisors first reported a position in TEVA in Q4 2021 and held it in 12 quarters. The position peaked at $7.97K in Q2 2024. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Rise Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Rise Advisors sold 250 Teva Pharmaceuticals shares in Q4 2024, an estimated $4.51K.
  • Rise Advisors first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Rise Advisors's Teva Pharmaceuticals position peaked at $7.97K in Q2 2024.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.